NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $3.39 -0.02 (-0.59%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.40 +0.01 (+0.35%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About C4 Therapeutics Stock (NASDAQ:CCCC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get C4 Therapeutics alerts:Sign Up Key Stats Today's Range$3.38▼$3.4850-Day Range$3.39▼$4.2652-Week Range$1.69▼$5.17Volume1.63 million shsAverage Volume1.84 million shsMarket Capitalization$417.07 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingModerate Buy Company Overview C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses targeted protein degradation, an approach designed to recruit the body’s natural protein-disposal system to remove specific proteins rather than simply inhibit their activity. C4 Therapeutics develops its drug candidates through its proprietary TORPEDO platform, which is intended to identify and optimize small-molecule degraders for challenging biological targets. Its research and development programs have included investigational therapies for cancer, including candidates designed to target proteins involved in tumor growth and survival, such as KRAS G12C and BRD9. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics conducts research and clinical-development activities primarily in the United States. The company has also pursued strategic collaborations with larger pharmaceutical companies to advance targeted protein-degradation research and potential therapies.AI Generated. May Contain Errors. Read More C4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCCCC MarketRank™: C4 Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 663rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialC4 Therapeutics has a consensus price target of $7.67, representing about 126.2% upside from its current price of $3.39.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($0.85) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.22% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 16.74, which indicates bearish sentiment.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 9.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. News and Social Media4.0 / 5News SentimentN/A News SentimentC4 Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for C4 Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CCCC Stock News HeadlinesC4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide ReadoutsSeptember 5, 2026 | seekingalpha.comC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple ...September 3, 2026 | markets.businessinsider.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 20 at 1:00 AM | Paradigm Press (Ad)C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingSeptember 3, 2026 | globenewswire.comC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | finance.yahoo.comC4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?July 3, 2026 | insidermonkey.comC4 Therapeutics Shareholders Back Directors, Pay and AuditorsJune 24, 2026 | tipranks.comC4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - SlideshowJune 20, 2026 | seekingalpha.comSee More Headlines CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $1.91 at the beginning of the year. Since then, CCCC stock has increased by 77.5% and is now trading at $3.39. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Tuesday, August, 11th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The company had revenue of $6.64 million for the quarter, compared to analyst estimates of $4 million. C4 Therapeutics had a negative net margin of 289.44% and a negative trailing twelve-month return on equity of 45.45%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $163 million in an IPO on Friday, October 2nd 2020. The company issued 9,600,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? Top institutional investors of C4 Therapeutics include Wasatch Advisors LP (3.19%), Velan Capital Investment Management LP (0.46%), Seven Fleet Capital Management LP (0.31%) and Bank of New York Mellon Corp (0.23%). Insiders that own company stock include Leonard Reyno and Scott N Boyle. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of C4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/11/2026Today9/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CCCC's financial health is in the Green zone, according to TradeSmith. CCCC has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CCCC CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees104Year Founded2015Price Target and Rating Average Price Target for C4 Therapeutics$7.67 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+126.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$104.99 million Net Margins-289.44% Pretax Margin-289.09% Return on Equity-45.45% Return on Assets-30.90% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$35.95 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book1.28Miscellaneous Outstanding Shares123,030,000Free Float116,136,000Market Cap$417.07 million OptionableOptionable Beta2.94 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CCCC) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts